Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.

“We are pleased to be advancing ALKS 37 quickly through the clinic as it may have the potential to reverse this severe side effect of opioid administration with low systemic exposure and little to no central nervous system penetration”

“We are pleased to be advancing ALKS 37 quickly through the clinic as it may have the potential to reverse this severe side effect of opioid administration with low systemic exposure and little to no central nervous system penetration,” said Dr. Elliot Ehrich, Chief Medical Officer of Alkermes. “ALKS 37, one of several proprietary product candidates in our growing clinical pipeline, is an excellent example of how the company is leveraging its unique understanding of opioid biology and pharmacology to develop medications with potential advantages over currently available therapies.”

This phase 1 multidose study follows completion of a previous single dose clinical study in healthy volunteers, which showed that ALKS 37 was generally well tolerated and demonstrated low systemic exposure across a wide range of doses. These results will support a phase 2 clinical study of ALKS 37, which will assess the safety, tolerability and efficacy of ALKS 37 in individuals with OIC. The phase 2 study is expected to begin in the first half of calendar 2010.

SOURCE Alkermes, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Do probiotics really benefit healthy people?